• Bispecific antibody targets VEGF-A, angiopoietin-2 in DME

    11 monthes ago - By Healio

    Jason Ehrlich
    The bispecific monoclonal antibody RG7716, which binds to and inactivates both VEGF-A and angiopoietin-2, met its primary endpoint of significant improvement in best corrected visual acuity compared with ranibizumab treatment in a phase 2 study of patients with diabetic macular edema, according to a news release from Genentech, a member of the Roche group.
    Results from the BOULEVARD study were delivered at Angiogenesis, Exudation, and Degeneration 2018 hosted by Bascom Palmer Eye Institute in Miami.
    Monthly intravitreal injections of either 1.5 mg or 6 mg of RG7716 or of 0.3 mg
    Read more ...